Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key Metrics

Core Insights - BeiGene, Ltd. reported $1.12 billion in revenue for Q1 2025, marking a 48.6$1.22 compared to -$2.41 a year ago [1] - The revenue matched the Zacks Consensus Estimate of$1.12 billion, resulting in a slight surprise of -0.65%, while the EPS exceeded expectations with a surprise of +271.83% [1] Financial Performance - Product revenue totaled $1.11 billion, slightly below the estimated$1.12 billion by analysts [4] - Key product revenues included: - BRUKINSA (Zanubrutinib): $791.66 million vs.$820.07 million estimated - Tislelizumab: $171.16 million vs.$171.33 million estimated - XGEVA: $70.42 million vs.$56.55 million estimated - Other: $17.90 million vs.$14.28 million estimated - POBEVCY: $13.75 million vs.$16.11 million estimated - BLINCYTO: $23.91 million vs.$20.42 million estimated - KYPROLIS: $19.73 million vs.$16.51 million estimated - Collaboration revenue was $8.75 million, exceeding the$6.49 million estimate [4] Market Performance - BeiGene's shares have returned +15.4% over the past month, outperforming the Zacks S&P 500 composite's +10.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]